Hookipa Pharma (HOOK) Competitors $0.85 -0.07 (-7.22%) Closing price 04:00 PM EasternExtended Trading$0.87 +0.02 (+2.18%) As of 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HOOK vs. CNTX, TNXP, PEPG, MRSN, VTVT, KPTI, IMRX, ONCY, CTMX, and PDSBShould you be buying Hookipa Pharma stock or one of its competitors? The main competitors of Hookipa Pharma include Context Therapeutics (CNTX), Tonix Pharmaceuticals (TNXP), PepGen (PEPG), Mersana Therapeutics (MRSN), vTv Therapeutics (VTVT), Karyopharm Therapeutics (KPTI), Immuneering (IMRX), Oncolytics Biotech (ONCY), CytomX Therapeutics (CTMX), and PDS Biotechnology (PDSB). These companies are all part of the "pharmaceutical preparations" industry. Hookipa Pharma vs. Context Therapeutics Tonix Pharmaceuticals PepGen Mersana Therapeutics vTv Therapeutics Karyopharm Therapeutics Immuneering Oncolytics Biotech CytomX Therapeutics PDS Biotechnology Hookipa Pharma (NASDAQ:HOOK) and Context Therapeutics (NASDAQ:CNTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, community ranking, profitability, media sentiment, analyst recommendations, risk and institutional ownership. Which has stronger valuation and earnings, HOOK or CNTX? Context Therapeutics has lower revenue, but higher earnings than Hookipa Pharma. Context Therapeutics is trading at a lower price-to-earnings ratio than Hookipa Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHookipa Pharma$43.95M0.23-$81.58M-$3.52-0.24Context TherapeuticsN/AN/A-$23.96M-$0.49-1.47 Does the media refer more to HOOK or CNTX? In the previous week, Context Therapeutics had 3 more articles in the media than Hookipa Pharma. MarketBeat recorded 3 mentions for Context Therapeutics and 0 mentions for Hookipa Pharma. Context Therapeutics' average media sentiment score of 0.25 beat Hookipa Pharma's score of 0.00 indicating that Context Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Hookipa Pharma Neutral Context Therapeutics Neutral Does the MarketBeat Community believe in HOOK or CNTX? Hookipa Pharma received 68 more outperform votes than Context Therapeutics when rated by MarketBeat users. However, 76.67% of users gave Context Therapeutics an outperform vote while only 69.47% of users gave Hookipa Pharma an outperform vote. CompanyUnderperformOutperformHookipa PharmaOutperform Votes9169.47% Underperform Votes4030.53% Context TherapeuticsOutperform Votes2376.67% Underperform Votes723.33% Is HOOK or CNTX more profitable? Context Therapeutics has a net margin of 0.00% compared to Hookipa Pharma's net margin of -86.74%. Hookipa Pharma's return on equity of -33.31% beat Context Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Hookipa Pharma-86.74% -33.31% -21.65% Context Therapeutics N/A -58.76%-55.80% Do institutionals and insiders hold more shares of HOOK or CNTX? 63.9% of Hookipa Pharma shares are held by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are held by institutional investors. 3.3% of Hookipa Pharma shares are held by company insiders. Comparatively, 3.0% of Context Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts prefer HOOK or CNTX? Hookipa Pharma currently has a consensus price target of $23.00, indicating a potential upside of 2,604.29%. Context Therapeutics has a consensus price target of $6.17, indicating a potential upside of 757.67%. Given Hookipa Pharma's higher probable upside, research analysts clearly believe Hookipa Pharma is more favorable than Context Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hookipa Pharma 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Context Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Which has more risk & volatility, HOOK or CNTX? Hookipa Pharma has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500. Comparatively, Context Therapeutics has a beta of 2.06, meaning that its stock price is 106% more volatile than the S&P 500. SummaryContext Therapeutics beats Hookipa Pharma on 10 of the 18 factors compared between the two stocks. Remove Ads Get Hookipa Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for HOOK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HOOK vs. The Competition Export to ExcelMetricHookipa PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.26M$6.73B$5.54B$7.49BDividend YieldN/A2.79%5.35%4.04%P/E Ratio-0.236.9923.2518.07Price / Sales0.23198.60361.2686.80Price / CashN/A65.6738.1634.64Price / Book0.095.926.493.99Net Income-$81.58M$142.37M$3.21B$247.18M7 Day Performance-29.13%-9.32%-6.42%-6.42%1 Month Performance-39.68%-10.26%-0.68%-7.44%1 Year Performance-88.94%-15.08%6.05%-4.31% Hookipa Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HOOKHookipa Pharma1.7445 of 5 stars$0.85-7.2%$23.00+2,604.3%-87.9%$10.26M$43.95M-0.2356CNTXContext Therapeutics2.0228 of 5 stars$0.76-1.0%$6.17+707.2%-49.9%$57.30MN/A-0.847Gap UpTNXPTonix Pharmaceuticals2.4173 of 5 stars$30.51+32.5%$585.00+1,817.4%-97.1%$57.02M$10.09M-0.0150Upcoming EarningsGap DownHigh Trading VolumePEPGPepGen2.1145 of 5 stars$1.70-4.0%$10.33+507.8%-88.8%$55.58MN/A-0.5730MRSNMersana Therapeutics4.186 of 5 stars$0.44+4.6%$4.00+799.3%-91.9%$55.44M$40.50M-0.73150Short Interest ↓Gap DownVTVTvTv Therapeutics1.6006 of 5 stars$17.37+4.4%$35.00+101.5%-31.5%$55.41M$1.02M-3.839Gap DownKPTIKaryopharm Therapeutics3.3516 of 5 stars$6.51+1.4%$57.50+783.3%-80.6%$54.80M$145.24M-6.38380Gap DownIMRXImmuneering3.354 of 5 stars$1.74-3.3%$11.00+532.2%-37.6%$54.03M$320,000.00-0.8860Short Interest ↓News CoveragePositive NewsGap DownONCYOncolytics Biotech1.3006 of 5 stars$0.63-0.1%$4.00+535.6%-51.2%$53.81MN/A-2.3330Gap DownCTMXCytomX Therapeutics4.0952 of 5 stars$0.67+0.4%$5.02+649.9%-71.6%$53.65M$138.10M3.94170Analyst DowngradeGap DownPDSBPDS Biotechnology1.8162 of 5 stars$1.37flat$11.67+751.6%-69.0%$52.32MN/A-1.1820Earnings ReportShort Interest ↓Gap Down Remove Ads Related Companies and Tools Related Companies Context Therapeutics Competitors Tonix Pharmaceuticals Competitors PepGen Competitors Mersana Therapeutics Competitors vTv Therapeutics Competitors Karyopharm Therapeutics Competitors Immuneering Competitors Oncolytics Biotech Competitors CytomX Therapeutics Competitors PDS Biotechnology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HOOK) was last updated on 4/3/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hookipa Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Hookipa Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy HOOK Stock Free HOOK Stock Alerts